> Management

Mathieu CHARVERIAT, CEO & Chairman

Mathieu Charvériat holds degrees from the École Polytechnique and Mines ParisTech, as well as a PhD in neurosciences and cell biology from the Université Pierre & Marie Curie. He also participated in the HEC Challenge + entrepreneur program with Franck Mouthon. He joined the neurosciences research laboratory of the French Alternative Energies and Atomic Energy Commission (CEA) in 2009, working with Franck Mouthon on prion diseases and non-neuronal cells, where together they published various papers and filed several patents related to the modulation of drugs targeting neurons. In March 2013, he co-founded Theranexus with Franck Mouthon. He is CEO and Chairman.

Julien VEYS, Chief Operating Officer

Julien Veys holds a master’s degree in biochemistry and in information and intelligence management from Aix-Marseille University. He has 15 years of experience in the health industry. After working for a contract research organization (CRO), he joined Trophos (a biotech company specialized in neurodegenerative diseases) in 2005, where he held various successive positions, including Chief Business Development Officer, up until the sale of Trophos to Roche Laboratories for €470 million in 2015. He became Chief Business Development Officer of Theranexus in early 2016, and the Chief Operating Officer ; he also serves as Administrator of Theranexus.

Marie SEBILLE, Chief Medical Officer

Marie is an MD by training and holds a PhD in neurosciences. She has almost 30 years of experience in the pharmaceutical industry, where she has worked in various positions as a physician in Global Medical and Global Clinical Development. She contributed to the development of multiple drugs in neurology and psychiatry, then she held several executive positions managing Clinical Operations in Sanofi R&D. During her tenure, Marie’s organization supported all major registration files in Rare Diseases, Oncology, I&I and Diabetes & Metabolism, as well as Life Cycle Management programs.  Marie joined Theranexus in 2021 as Chief Medical Officer.

Christine PLACET, Chief Financial Officer

Christine Placet graduated from Kedge Business School. After 8 years' experience with Ernst and Young, and 9 years of financial management in SMEs, in 2004 she joined the biotech Trophos as Chief Financial Officer and subsequently Chair of the Board of Directors until the company was sold to the Roche group for €470 M in 2015. In 2016, Christine Placet was appointed CEO of the biotech company Horama (now Coave Therapeutics). After two funding rounds of €4 M and €22 M, and initial product entry into the development phase, she recruited her successor to devote time to consulting from 2021 onwards. She joined Theranexus as Chief Financial Officer in April 2024.